Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC

This study will test a new potential treatment for advanced esophageal squamous cell cancer (ESCC) for patients whose initial treatment has stopped working. Currently, the standard second-line treatment for this cancer is PD-1 inhibitors or chemotherapy alone, which is not very effective, allowing the cancer to grow again after just 1.6 to 3.4 months on average. Therefore, there is a strong need for more effective therapies. The new treatment is a type of drug called an antibody-drug conjugate (ADC). It is designed to target a specific protein called EGFR, which is found in high amounts on th

Trial Details

NCT ID
NCT07403136
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Vebrekotuzumab
  • PD-1 antibody
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Willing to voluntarily sign the informed consent form and comply with the protocol requirements.
  • Age ≥18 years on the day of signing the informed consent form, regardless of gender.
  • Life expectancy ≥12 weeks.
  • Patients with histologically confirmed advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC) and immunohistochemistry (IHC) co…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →